Novelion's Chairman, Jason Aryeh, is the Founder and managing General Partner of JALAA Equities, LP, a private hedge fund focused on the Life Sciences sector, and has served in such capacity since 1997. Mr. Aryeh serves on the Board of Directors, as Chairman of the Nominating and Governance Committee and as a member of the Compensation Committee of Ligand Pharmaceuticals. Mr. Aryeh also serves on the Board of Directors of the Cystic Fibrosis Foundation's Therapeutics Board. Mr. Aryeh earned a B.A. in economics, with honors, from Colgate University, and is a member of the Omnicron Delta Epsilon Honor Society in economics.
Mr. Kotler has over 23 years of experience as an investor and analyst following the healthcare industry. He is the founder and Managing Partner of Broadfin Capital, LLC which is the investment advisor for Broadfin Healthcare Master Fund, Ltd., a healthcare focused investment fund which he launched in 2005. Mr. Kotler earned a B.S. in economics from the Wharton School at the University of Pennsylvania in 1993
John Orloff, M.D., is Executive Vice President, Head of Research & Development of Alexion. Dr. Orloff has 20 years of experience in the biopharmaceutical industry and deep expertise spanning various stages of clinical and non-clinical development, including developing medicines for rare diseases. Prior to joining Alexion, Dr. Orloff served as Executive Vice President, Head of Research & Development at Novelion. He previously served with Baxalta as Global Head of R&D and Chief Scientific Officer, where he advanced the company's pipeline and oversaw regulatory approval of 10 unique products and two devices. He also held executive R&D roles with Baxter International, Merck Serono, Novartis and Merck Research Laboratories. Prior to joining the biopharmaceutical industry in 1997, Dr. Orloff was with the Yale School of Medicine for seven years. Dr. Orloff received a Bachelor of Arts from Dartmouth College, and a M.D. from the University of Vermont College of Medicine. He completed his medical training at the University of Pittsburgh Medical Center and Yale University School of Medicine.
Prior to being appointed to Novelion's Board of Directors, Jorge Plutzky was a member of Aegerion Pharmaceuticals' Board of Directors since April 2015. Dr. Plutzky is the Director of Preventive Cardiology, which includes the Lipid/Prevention Clinic, in the Cardiovascular Medicine Division at Brigham and Women’s Hospital. Since 1995, he has been on the faculty at Harvard Medical School and he continues to direct his own NIH-funded basic science laboratory. Dr. Plutzky has been a member of the scientific advisory boards of the Sarnoff Cardiovascular Research Foundation since 2009, where he is now Chair Elect, a member of the American Society for Clinical Investigation and is a Fellow of the American College of Cardiology.
Prior to being appointed to Novelion's Board of Directors, Stephen L. Sabba, M.D. was a Director of QLT since 2012, Chairman of the Audit and Risk Committee and a member of the Scientific Review and Compensation Committees. Currently, Dr. Sabba is also a Partner and Health Care Portfolio Manager at Knott Partners, LP (since 2006), an investment fund, and a Director of Ligand (since 2008), a public biotechnology company. Previously, he was a Partner and Director of Research with Kilkenny Capital Management (2001 to 2006), a Chicago-based hedge fund. Dr. Sabba received his medical degree from the New York University School of Medicine, and completed a residency in internal medicine and a fellowship in gastroenterology at the Veterans Administration Medical Center in New York City. He earned a Bachelor of Science degree with honors at Cornell University.
Prior to being appointed to Novelion's Board of Directors, Donald Stern was a member of Aegerion Pharmaceuticals' Board of Directors since September 2015. Mr. Stern is Managing Director of Corporate Monitoring & Consulting Services at Affiliated Monitors Inc., a consulting firm providing independent integrity monitoring services and compliance services across a wide range of regulated industries and professions. He is also Of Counsel to Yurko, Salvesen, & Remz, PC, a boutique litigation law firm in Boston. Mr. Stern was United States Attorney for the District of Massachusetts from 1993 to 2001. He was also the chair of the U.S. Attorney General's Advisory Committee from 1996 to 1998. Mr. Stern served as the chief legal counsel to Governor Michael S. Dukakis from 1987 to 1990. He also spent seven years (1975-1982) as an assistant attorney general in the Massachusetts Attorney General's office, where he held several positions, including Chief of the Government Bureau. Previously, Mr. Stern was a partner at three major law firms, Cooley LLP, Bingham McCutchen LLP, and Hale and Dorr LLP (now Wilmer Cutler Pickering Hale and Dorr LLP), where his law practice focused on internal investigations, white collar defense and business litigation. He has extensive experience representing companies and individuals in complex civil, criminal and regulatory matters, with clients across a spectrum of industries, including health care, pharmaceutical, and financial services. Mr. Stern was an Advisor to President Barack Obama's Justice Department Transition Team. He currently co-chairs the American Bar Association/DOJ White Collar Liaison Committee, and is a former President of the National Association of Former U.S. Attorneys. He was a liaison to the American Bar Association Task Force on Corporate Monitors. Mr. Stern has been on the faculty of Boston College Law School and Harvard Law School. He received his LL.M. from the University of Pennsylvania, his J.D. from Georgetown University Law Center, and his B.A. from Hobart College. He also received an honorary LL.D. from the New England School of Law. Mr. Stern is a member of the Board of Directors of Blue Cross and Blue Shield of Massachusetts.
Dr. Cox previously served as Interim Chief Executive Officer of QLT Inc. Previously, Dr. Cox served as an independent consultant to the life sciences industry. From 2001 to 2010, Dr. Cox was Chairman, President and CEO of GTC Biotherapeutics Inc. (now rEVO Biologics), and from 1997 to 2001 he was Chairman, President and CEO of Aronex Pharmaceuticals Inc. Prior to that, he served at Genzyme Corporation Inc., last serving as its Executive Vice President, Operations. Dr. Cox is a former Chairman of MassBio, the Massachusetts Biotechnology Council, and served for a number of years on the Board of the Biotechnology Industries Association (BIO). Dr. Cox holds a BSc. in biochemistry from the University of Birmingham, UK and a Ph.D. in biochemistry from the University of East Anglia, UK.
Mary Szela was appointed chief executive officer of Aegerion Pharmaceuticals in January 2016. Previously, Ms. Szela was chief executive officer of Melinta Therapeutics until August 2015, where she led the company’s revitalization effort, accelerated the lead asset into three phase programs and oversaw key business development transactions to monetize non-core assets. Before joining Melinta, she held various management positions at Abbott Laboratories, most recently as senior vice president for global strategic marketing and services. From 2008 to 2010, Ms. Szela served as president of the $8 billion U.S. pharmaceuticals division, during which time she directed the development and launch of more than eight new pharmaceutical products and multi-billion dollar sales growth for Abbott’s flagship product, Humira®. Between 2002 and 2008, Ms. Szela managed several of Abbott’s billion-dollar U.S. pharmaceutical businesses, and was VP of U.S. commercial operations. Prior to 2001, Ms. Szela held a series of leadership positions in the Abbott Hospital Products Division. She currently serves as a member of the boards of Coherus Biosciences, and Suneva Medical. Ms. Szela earned an M.B.A. and a B.S. in nursing from the University of Illinois.
Mark Corrigan was previously president and chief executive officer of Zalicus Inc. Prior to that, he was executive vice president, research & development of Sepracor Inc. (now Sunovion Pharmaceuticals). Prior to joining Sepracor, Dr. Corrigan spent 10 years with Pharmacia & Upjohn, Inc., most recently as group vice president of global clinical research and experimental medicine. Dr. Corrigan currently serves on the board of directors of Cardiome Pharma Corp. (NASDAQ: CRME) and on the supervisory board of Nabriva Therapeutics AG (NASDAQ: NBRV). He previously served as a director of CoLucid Pharmaceuticals, Inc., Avanir Pharmaceuticals, Inc., EPIRUS Biopharmaceuticals, Inc. and Cubist Pharmaceuticals, Inc. He was chairman of the board of EPIRUS and served on the audit committee and nominating and governance committee and chaired the scientific affairs committee of Cubist's board. Dr. Corrigan spent five years in academic research at the University of North Carolina Medical School, focusing on psychoneuroendocrinology. Dr. Corrigan holds a B.A. and an M.D. from the University of Virginia and received specialty training in psychiatry at Maine Medical Center and Cornell University.